scholarly journals SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?

2020 ◽  
Vol 90 (4) ◽  
Author(s):  
Maddalena Giglia ◽  
Giacomo Beci ◽  
Elena Rosselli Del Turco ◽  
Viola Guardigni ◽  
Alberto Amedeo ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Adult Patient ◽  
Clinical Improvement ◽  
Clinical Course ◽  
Effective Therapy ◽  
Total Recovery ◽  
First Case ◽  
Significant Clinical Improvement

We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.

scholarly journals Alternative Leprosy Treatment Using Rifampicin Ofloxacin Minocycline (ROM) Regimen – Two Case Reports

2019 ◽  
Vol 11 (3) ◽  
pp. 89-93
Author(s):  
Yohanes Widjaja ◽  
Khairuddin Djawad ◽  
Saffruddin Amin ◽  
Widyawati Djamaluddin ◽  
Dirmawati Kadir ◽  
...  
Keyword(s):  
Clinical Improvement ◽  
Alternative Treatment ◽  
Histopathological Examination ◽  
Case Reports ◽  
Erythematous Plaque ◽  
First Case ◽  
Satisfactory Outcome ◽  
Significant Clinical Improvement ◽  
The Right

Abstract Introduction. Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in neuropathy and associated long-term consequences, including deformities and disabilities. According to the WHO classification, there are two categories of leprosy, paucibacillary (PB) and multibacillary (MB). The standard treatment for leprosy employs the use of WHO MDT (Multi Drug Treatment) regimen, despite its multiple downsides such as clofazimine-induced pigmentation, dapsone-induced haematological adverse effects, poor compliance due to long therapy duration, drug resistance, and relapse. Multiple studies and case reports using ROM regimen have reported satisfactory results. Nevertheless, there are still insufficient data to elucidate the optimum dosage and duration of ROM regimen as an alternative treatment for leprosy. Previous experience from our institution revealed that ROM regimen given three times weekly resulted in a satisfactory outcome. Case Reports. We report two cases of leprosy treated with ROM regimen from our institution. The first case was PB leprosy in a 64-year-old male who presented with a single scaly plaque with erythematous edge on the right popliteal fossa. Sensibility examination showed hypoesthesia with no peripheral nerve enlargement. Histopathological examination confirmed Borderline Tuberculoid leprosy. ROM regimen was started three times weekly for 6 weeks and the patient showed significant clinical improvement at the end of the treatment with no reaction or relapse until after 6 months after treatment. The second case was MB leprosy in a 24-year-old male patient with clawed hand on the 3rd-5th phalanges of the right hand and a hypoesthetic erythematous plaque on the forehead. Histopathology examination confirmed Borderline leprosy. The patients received ROM therapy 3 times a week with significant clinical improvement after 12 weeks. Conclusion. ROM regimen given three times weekly for 6 weeks in PB leprosy and 12 weeks in MB leprosy resulted in a significant clinical improvement. Thus, ROM regimen could be a more effective, safer, faster alternative treatment for leprosy.

Arthropathy Secondary to Ciprofloxacin in an Adult Cystic Fibrosis Patient

1993 ◽  
Vol 27 (3) ◽  
pp. 302-303 ◽  
Author(s):  
Wayne M. Samuelson ◽  
Roy A. Pleasants ◽  
Martha S. Whitaker
Keyword(s):  
Cystic Fibrosis ◽  
Adult Patient ◽  
Cystic Fibrosis Patient ◽  
Pediatric Patients ◽  
Prior History ◽  
Case Summary ◽  
First Case ◽  
Acute Exacerbations ◽  
History Of ◽  
Possible Cause

OBJECTIVE: To report a case of possible ciprofloxacin-induced arthropathy in an adult patient with cystic fibrosis (CF). CASE SUMMARY: A 25-year-old man with CF received three separate courses of ciprofloxacin therapy at usual doses for acute pulmonary exacerbations of his disease. During the second and third courses, the patient experienced bilateral swelling of his knees between two to three weeks after initiation of each course. Both times symptoms markedly decreased after discontinuation of the drug. The patient had no prior history of arthropathy. Furthermore, during the last two acute exacerbations of his CF, he did not receive ciprofloxacin and did not experience any symptoms of arthropathy. DISCUSSION: Prior cases of quinolone-induced arthropathy involving pediatric CF patients or adult patients without CF have been reported in the literature. We report the first case of such an arthropathy in an adult patient with CF. The findings are supported by a rechallenge with the drug. CONCLUSIONS: It is likely that ciprofloxacin may produce arthropathy in adult as well as pediatric patients with CF. Quinolones should be considered as a possible cause of arthropathy in adult CF patients.

scholarly journals A Knowledge-Based Algorithm for Automatic Monitoring of Orthodontic Treatment: The Dental Monitoring System. Two Cases

Sensors ◽  
2021 ◽  
Vol 21 (5) ◽  
pp. 1856
Author(s):  
Silvia Caruso ◽  
Sara Caruso ◽  
Marianna Pellegrino ◽  
Rayan Skafi ◽  
Alessandro Nota ◽  
...  
Keyword(s):  
Adult Patient ◽  
Remote Monitoring ◽  
Digital Technology ◽  
Orthodontic Treatment ◽  
Dental Treatment ◽  
Automatic Monitoring ◽  
Software As A Service ◽  
Knowledge Based ◽  
First Case ◽  
Service Application

Background: In the dental field, digital technology has created new opportunities for orthodontists to integrate their clinical practice, and for patients to collect information about orthodontics and their treatment, which is called “teledentistry.” Dental monitoring (DM) is a recently introduced orthodontic application that combines safe teledentistry with artificial intelligence (AI) using a knowledge-based algorithm, allowing an accurate semi-automatic monitoring of the treatment. Dental Monitoring is the world’s first SaaS (Software as a Service) application designed for remote monitoring of dental treatment, developed in Paris, France, with Philippe Salah as the Co-founder and CEO. Cases presentation: This report describes two cases in which DM system was essential to achieve the control of certain movements: it was possible to follow the movement, even if complex, such as the anterior cross of an adult patient and a lack of space in the canine of the growing patient. The software analyzed the fit and retention of the aligner, thus ensuring correct biomechanics. They were treated during the COVID-19 pandemic lockdown with aligners. The first case is a growing patient who was monitored during an interceptive orthodontic treatment to manage a retained upper canine. The second case is an adult patient forced to finalize his treatment of upper lateral incisor crossbite. The software analyzed the fit and retention of the aligner, thus ensuring correct biomechanics. Conclusions: DM system appears to be a promising method, useful for improving the interaction between doctor and patient, generally acceptable and useful to patients, even in critical clinical situations, at least in cases with optimal compliance and ability to use the tool properly.

scholarly journals Acute Cholecystitis Caused by Ceftriaxone Stones in an Adult

2009 ◽  
Vol 2009 ◽  
pp. 1-2 ◽  
Author(s):  
Christian D. Becker ◽  
Robert A. Fischer
Keyword(s):  
Adult Patient ◽  
Acute Cholecystitis ◽  
Health Problem ◽  
Medical Literature ◽  
Early Recognition ◽  
Gallstone Formation ◽  
Sludge Formation ◽  
Major Health Problem ◽  
Major Health ◽  
First Case

Acute cholecystitis is a major health problem. There are multiple etiologies to be considered and early recognition of the condition is important to optimize management and outcome. We report the first case in the medical literature of symptomatic acute cholecystitis triggered by ceftriaxone-associated gallbladder sludge formation and, importantly, solid ceftriaxone gallstone formation in an adult patient with underlying mineral and pigment cholecystolithiasis, necessitating cholecystectomy. This case serves as a reminder for physicians to keep this uncommon cause of cholecystolithiasis and cholecystitis in mind in patients who receive prolonged ceftriaxone therapy. These patients should be cautioned to promptly report to their physicians any signs or symptoms of cholecystitis in order to ensure timely and appropriate evaluation.

scholarly journals The use of a handmade balloon-expandable covered stent for native coarctation of the aorta in an adult patient: A report of a first case in Japan

2010 ◽  
Vol 56 (3) ◽  
pp. 287-290
Author(s):  
Takashi Higaki ◽  
Eiichi Yamamoto ◽  
Masahiro Ryugo ◽  
Hiroshi Imagawa ◽  
Fumiaki Shikata ◽  
...  
Keyword(s):  
Adult Patient ◽  
Coarctation Of The Aorta ◽  
Covered Stent ◽  
First Case

Synopsis of Pathology

PEDIATRICS ◽  
1961 ◽  
Vol 27 (3) ◽  
pp. 451-451
Keyword(s):  
Cystic Fibrosis ◽  
Adult Patient ◽  
Pneumocystis Pneumonia ◽  
Current Interest ◽  
Specific Interest ◽  
General Pathology

The new edition of the synopsis remains the only textbook on pathology concise enough to be taken in one's pocket and yet complete enough to provide some valuable information and a good reference on many subjects. This book will certainly be useful for the busy practitioner trying to refresh hazy memories on general pathology and problems of the adult patient. The information available on problems of specific interest to the pediatrician is, as could be expected in such an abridged text, scant and sketchy. There are, however, excellent "concentrated" descriptions of some pediatric conditions, e.g., cystic fibrosis of the pancreas; problems of current interest are mentioned, such as pneumocystis pneumonia and measles pneumonia.

A Therapeutic Trial of Fatty Acid Supplementation in Cystic Fibrosis

PEDIATRICS ◽  
1976 ◽  
Vol 57 (4) ◽  
pp. 474-479
Author(s):  
Robert B. Elliott
Keyword(s):  
Cystic Fibrosis ◽  
Fatty Acid ◽  
Clinical Course ◽  
Therapeutic Trial ◽  
Biochemical Abnormality ◽  
Fatty Acid Supplementation ◽  
Oil Emulsion ◽  
Soya Oil ◽  
One Year ◽  
Better Than

Seven children with cystic fibrosis (CF) have been treated for at least one year with intravenously administered soya oil emulsion. In all, an improvement of at least one biochemical abnormality in character with the disease appeared. The children's clinical course remains benign. This course is remarkably better than that of other children with CF treated without Intralipid in Auckland in the same period, though a placebo effect cannot be discounted. It is postulated that intravenous supplementation with essential fatty acid in CF may in turn partially correct an error of metabolism of prostaglandins present in the disease.

scholarly journals Mycobacterium talmoniae, a Potential Pulmonary Pathogen Isolated from Multiple Patients with Bronchiectasis in the United States, Including the First Case of Clinical Disease in a Patient with Cystic Fibrosis

2018 ◽  
Vol 57 (2) ◽  
Author(s):  
Ravikiran Vasireddy ◽  
Sruthi Vasireddy ◽  
Barbara A. Brown-Elliott ◽  
Alexander L. Greninger ◽  
Rebecca M. Davidson ◽  
...  
Keyword(s):  
United States ◽  
Cystic Fibrosis ◽  
16S Rrna ◽  
Type Strain ◽  
Gene Sequencing ◽  
The United States ◽  
Average Nucleotide Identity ◽  
Content Type ◽  
First Case ◽  
Multiple Patients

ABSTRACTWe characterize three respiratory isolates of the recently described speciesMycobacterium talmoniaerecovered in Texas, Louisiana, and Massachusetts, including the first case of disease in a patient with underlying cystic fibrosis. The three isolates had a 100% match toM. talmoniaeNE-TNMC-100812Tby complete 16S rRNA,rpoBregion V, andhsp65 gene sequencing. Core genomic comparisons between one isolate and the type strain revealed an average nucleotide identity of 99.8%. The isolates were susceptible to clarithromycin, amikacin, and rifabutin, while resistance was observed for tetracyclines, ciprofloxacin, and linezolid.M. talmoniaeshould be added to the list of potential pulmonary pathogens, including in the setting of cystic fibrosis.

scholarly journals Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis

Biomolecules ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. 136 ◽  
Author(s):  
Levent Kilic ◽  
Abdulsamet Erden ◽  
Yusuf Sener ◽  
Berkan Armagan ◽  
Alper Sari ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Improvement ◽  
Inflammatory Diseases ◽  
Case Series ◽  
New Drugs ◽  
Renal Amyloidosis ◽  
Secondary Amyloidosis ◽  
Aa Amyloidosis ◽  
Amyloid A ◽  
Significant Clinical Improvement

Secondary amyloid A (AA) amyloidosis is a late and serious complication of poorly controlled, chronic inflammatory diseases. Rheumatoid arthritis (RA) patients with poorly controlled, longstanding disease and those with extra-articular manifestations are under risk for the development of AA amyloidosis. Although new drugs have proven to be significantly effective in the treatment of secondary AA amyloidosis, no treatment modality has proven to be ideal. To date, only in small case series preliminary clinical improvement have been shown with rituximab therapy for AA amyloidosis secondary to RA that is refractory to TNF-α inhibitors (TNF-i) therapy. In these case series, we assessed the efficacy and safety of rituximab therapy for patients with RA and secondary amyloidosis. Hacettepe University Biologic Registry was developed at 2005. The data of the RA patients who were prescribed a biological drug were recorded regularly. Patients with biopsy proven AA amyloidosis patients were screened. Of 1022 RA patients under biologic therapy, 0.7% patients had clinically apparent histologically confirmed amyloidosis. Four of seven patients who were prescribed rituximab at least one infusion enrolled to those case series. Two of four patients showed significant clinical improvement and one of them also had decrease in proteinuria and the other one had stable renal function and proteinuria. The main goal for the treatment of AA amyloidosis is to control the activity of the underlying disorder. In this study, we showed that rituximab may be an effective treatment in RA patients with amyloidosis who were unresponsive to conventional disease modifying anti-rheumatic drugs (DMARDs) and/or TNFi.

Sign in / Sign up

Export Citation Format

Share Document